BOT - Anything but charting, page-8469

It's one of the things that I like about this drug, and the Acne formulation as well for that matter which I maintain is the real revenue giant if approved, is they don't cure the problem. They only treat the symptoms. So if this formulation works as intended for x% of the population then logic dictates most should return and the patient base will consistently grow as new prospective patients are born and are afflicted with the condition - Long term view.
Acne is the one I am most exited for - the target population is massive and it hit's the cosmetic / vanity sweet spot that redefines the drug into a must have for basically anyone going through puberty and it's a self generating patient pool as everyone goes through puberty and a high % of people suffer acne during that time.
Probably a rather callous point of view from the patients perspective but from a Revenue perspective ...........